Literature DB >> 16708764

Multiplex dosage pyrophosphorolysis-activated polymerization: application to the detection of heterozygous deletions.

Qiang Liu1, Vu Q Nguyen, Xuemin Li, Steve S Sommer.   

Abstract

Large heterozygous chromosomal deletions and gene duplications are important classes of mutations that are generally missed by standard PCR amplification and sequencing. Multiplex dosage pyrophosphorolysis-activated polymerization (MD-PAP), a derivative of PAP, was utilized to detect these types of mutations. PAP is a method for nucleic acid amplification in which 3' blocked oligonucleotides (P*) are activated by pyrophosphorolysis when annealed to the target template and subsequently extended. A key advantage to this technology is that PAP reactions produce little or no primer-dimer or false priming. As a result of this enhanced specificity, MD-PAP is easy to optimize. Herein, we utilize MD-PAP to determine gene dosage of each exon of the human factor IX gene by comparison with one endogenous internal control from the ATM gene. Estimated dosage is proportional to the actual template copy number over a minimum dynamic range from 1 to 16 copies. A blinded analysis detected 100% of 43 heterozygous deletions of exons in the human factor IX gene.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16708764     DOI: 10.2144/000112164

Source DB:  PubMed          Journal:  Biotechniques        ISSN: 0736-6205            Impact factor:   1.993


  2 in total

1.  Mass-spectrometry analysis of modifications at DNA termini induced by DNA polymerases.

Authors:  Igor P Smirnov; Natalia A Kolganova; Vadim A Vasiliskov; Alexander V Chudinov; Edward N Timofeev
Journal:  Sci Rep       Date:  2017-07-27       Impact factor: 4.379

2.  Analysis of cancer mutation signatures in blood by a novel ultra-sensitive assay: monitoring of therapy or recurrence in non-metastatic breast cancer.

Authors:  Zhenbin Chen; Jinong Feng; Carolyn H Buzin; Qiang Liu; Lawrence Weiss; Kemp Kernstine; George Somlo; Steve S Sommer
Journal:  PLoS One       Date:  2009-09-28       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.